Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Trial Profile

Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs ADVM 043 (Primary) ; ADVM 043 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; First in man
  • Acronyms ADVANCE
  • Sponsors Adverum Biotechnologies
  • Most Recent Events

    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company plans to begin patient enrollment in this trial in the fourth quarter of 2017. The Company expects to report preliminary data from this trial in the second half of 2018.
    • 05 Oct 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top